• Publications
  • Influence
International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma
Introduction: Adenocarcinoma is the most common histologic type of lung cancer. To address advances in oncology, molecular biology, pathology, radiology, and surgery of lung adenocarcinoma, anExpand
  • 2,229
  • 161
  • PDF
The 2015 World Health Organization Classification of Lung Tumors: Impact of Genetic, Clinical and Radiologic Advances Since the 2004 Classification.
The 2015 World Health Organization (WHO) Classification of Tumors of the Lung, Pleura, Thymus and Heart has just been published with numerous important changes from the 2004 WHO classification. TheExpand
  • 1,323
  • 62
  • PDF
Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the
Context: In 2013, an evidence‐based guideline was published by the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for MolecularExpand
  • 365
  • 44
Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis.
PURPOSE The epidermal growth factor receptor (EGFR) is frequently overexpressed in non-small-cell lung carcinoma (NSCLC), and EGFR inhibitors are promising new therapeutic agents. The molecularExpand
  • 1,229
  • 39
Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas.
  • C. Chung, K. Ely, +14 authors F. Hirsch
  • Medicine, Biology
  • Journal of clinical oncology : official journal…
  • 1 September 2006
PURPOSE High epidermal growth factor receptor (EGFR) gene copy number is associated with poor prognosis in lung cancer, but such findings have not been reported for HNSCC. A better understanding ofExpand
  • 498
  • 30
PD‐L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD‐L1 IHC Assay Comparison Project
Introduction: The Blueprint Programmed Death Ligand 1 (PD‐L1) Immunohistochemistry (IHC) Assay Comparison Project is an industrial‐academic collaborative partnership to provide information on theExpand
  • 646
  • 24
Restoring E-cadherin expression increases sensitivity to epidermal growth factor receptor inhibitors in lung cancer cell lines.
The epidermal growth factor receptor (EGFR) is overexpressed in the majority of non-small cell lung cancers (NSCLC). EGFR tyrosine kinase inhibitors, such as gefitinib and erlotinib, produce 9% toExpand
  • 471
  • 24
  • PDF
Lung cancer: current therapies and new targeted treatments
Lung cancer is the most frequent cause of cancer-related deaths worldwide. Every year, 1·8 million people are diagnosed with lung cancer, and 1·6 million people die as a result of the disease. 5-yearExpand
  • 581
  • 22
  • PDF
Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar
PURPOSE Bronchioloalveolar carcinoma (BAC) and adenocarcinomas with BAC features seem to be increasing in incidence, particularly in younger, never-smoking women. Epidermal growth factor receptorExpand
  • 567
  • 19
International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society: international multidisciplinary classification of lung adenocarcinoma: executive summary.
INTRODUCTION The American Thoracic Society is a cosponsor of a newly published lung adenocarcinoma classification. METHODS An international multidisciplinary panel of experts was formed. AExpand
  • 379
  • 19